DealsHealth

Roche looking to sell or shut down California biologic drug plant

01 June 2023, 5:42 pm 1 minute

Reuters has exclusively seen documents indicating Swiss drugmaker Roche Holding AG (ROG.S) plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029.

Market Impact

Roche is under pressure to develop new treatments to offset the loss of billions in sales due to cheap biotech copies of its established cancer medicines Herceptin, Avastin and Rituxan.

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: SwitzerlandUnited States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

JPMorgan CEO Jamie Dimon to visit Africa in growth push

Roche looking to sell or shut down California biologic drug plant

Market Impact

More of Reuters Best

JPMorgan CEO Jamie Dimon to visit Africa in growth push

Ryanair raises summer fare outlook as ‘ugly scenario’ avoided

India flags cricket rights concerns with Disney-Reliance $8.5 bln merger

Custody giant State Street expands crypto services in new partnership